Conducted by the China Institute of Atomic Energy, a subsidiary of the China National Nuclear Corporation (CNNC), the development of the prototype of a high-current proton cyclotron for Boron Neutron Capture Therapy (BNCT) has passed its technical acceptance. This marks the successful development of the first domestically produced prototype of BNCT based on a high-current cyclotron.

The expert group listened to the technical summary report from the project team, examined the test results, and gave comments. They reached a consensus that the results met the requirements, completing all the specified research content, with some indicators exceeding the plan.

BNCT is one of the most cutting-edge targeted therapies for cancer in the international oncology field in recent years. It can be used in the treatment of cancers such as head and neck cancer and melanoma. The project team has tackled technological challenges of high-current cyclotron, neutron targets, and moderation body, and achieved the strong extraction capability of a small-scale cyclotron with a current of milliamperes. This provides a solid foundation for the subsequent standardization of BNCT equipment and clinical research, and effectively advances the transformation of the achievements in BNCT equipment, contributing to China's medical and health industry.